Paid Clinical Trials Billings
Discover 116 paid clinical trials in Billings, Montana. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
IvonescimabClinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients
Sponsor:
Summit Therapeutics
Location:
Code:
NCT05899608
Conditions
Non-Small Cell Lung Cancer
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Ivonescimab Injection
Pembrolizumab Injection
RAS(ON) Inhibitor CombinationsStudy of RAS(ON) Inhibitor Combinations in Patients with Advanced RAS-mutated NSCLC
Sponsor:
Revolution Medicines, Inc.
Location:
Code:
NCT06162221
Conditions
Non-Small Cell Lung Cancer, NSCLC
KRAS, NRAS, HRAS-mutated NSCLC
KRAS G12C-mutated Solid Tumors, Lung Cancer
Lung Cancer Stage IV, Advanced Solid Tumor, Cancer
RAS G12D-mutated NSCLC
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
RMC-6291
RMC-6236
Pembrolizumab
Cisplatin
Carboplatin
RetatrutideEffect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)
Sponsor:
Eli Lilly and Company
Location:
Code:
NCT06297603
Conditions
Type 2 Diabetes
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Retatrutide
Placebo
IanalumabStudy of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP)
Sponsor:
Novartis Pharmaceuticals
Location:
Code:
NCT05653349
Conditions
Primary Immune Thrombocytopenia (ITP)
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
Ianalumab
Placebo
Corticosteroids
Observational StudyImpact of Sentinel Lymph Node Mapping on Patient Reported Lower Extremity Limb Dysfunction in Stage I Endometrial Cancer
Sponsor:
NRG Oncology
Location:
Code:
NCT05646316
Conditions
Stage I Uterine Corpus Cancer AJCC v8
Eligibility Criteria
Sex: Female
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Biospecimen Collection
Diagnostic Imaging
Excisional Biopsy
Indocyanine Green Solution
Minimally Invasive Surgery
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Buccal Film vs. IV PalonosetronBuccal Film vs IV Palonosetron for Prevention of CINV in Cancer Patients Receiving MEC
Sponsor:
Xiamen LP Pharmaceutical Co., Ltd
Location:
Code:
NCT05199818
Conditions
Chemotherapy-induced Nausea and Vomiting
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Palonosetron HCl Buccal Film 0.5 mg
IV Palonosetron 0.25 mg
Tailoring TherapyTailoring Therapy in Post-surgical Patients With Low-risk Endometrial Cancer
Sponsor:
NRG Oncology
Location:
Code:
NCT06388018
Conditions
Stage I Uterine Corpus Endometrial Stromal Sarcoma AJCC v8
Stage II Uterine Corpus Endometrial Stromal Sarcoma AJCC v8
Stage III Uterine Corpus Endometrial Stromal Sarcoma AJCC v8
Eligibility Criteria
Sex: Female
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Clinical Observation
Computed Tomography
External Beam Radiation Therapy
High-Dose-Rate Vaginal Brachytherapy
Magnetic Resonance Imaging
Zilovertamab Vedotin & Standard of CareA Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
Sponsor:
Merck Sharp & Dohme LLC
Location:
Code:
NCT05139017
Conditions
DLBCL
Diffuse Large B-Cell Lymphoma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Zilovertamab vedotin
Rituximab
Gemcitabine
Oxaliplatin
Bendamustine
Patritumab Deruxtecan & PembrolizumabStudy of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
Sponsor:
Merck Sharp & Dohme LLC
Location:
Code:
NCT06797635
Conditions
Breast Neoplasms
Breast Cancer
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Patritumab deruxtecan
Pembrolizumab
Paclitaxel
Carboplatin
Doxorubicin hydrochloride
ImmunotherapyImmunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Sponsor:
National Cancer Institute (NCI)
Location:
Code:
NCT06498635
Conditions
Lung Non-Small Cell Carcinoma
Stage II Lung Cancer AJCC v8
Stage IIIA Lung Cancer AJCC v8
Stage IIIB Lung Cancer AJCC v8
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Biospecimen Collection
Computed Tomography
Durvalumab
Patient Observation
Questionnaire Administration